Project 1 will investigate means of improving the survival of patients with myeloid malignancies by reducing transplant-related mortality and relapse. In Project A, a regimen of cyclophosphamide (CY), total body irradiation (TBI) (15.75 Gy) and pentoxifylline (PTX) will be evaluated in patients with acute myeloid leukemia in first or second remission or untreated first relapse. Effects on relapse and transplant-related mortality will be determined. In Project B, attempts will be made to improve the survival of patients with chronic myeloid leukemia by comparing a regimen of busulfan (BU)/CY with CY/TBI. Attempts will be made to evaluate the significance of posttransplant relapse as defined by clinical, cytogenetic and PCR analyses. An attempt will be made to evaluate the practicality and benefits of interferon treatment prior to hematologic relapse. We will also carry out transplant studies in older patients (under age 66). In Project C, BU pharmacokinetics will be evaluated in patients receiving BU/CY/TBI. BU does will be specifically adjusted on the basis of predicted plasma levels for individual patients. If toxicity is diminished a dose escalation study based on targeted plasma levels will be carried out. If the dose escalation study is successful phase II and III studies will be carried out at the MTD based on targeted blood levels. Growth factors and pentoxifylline will be evaluated following completion of these studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA018029-17
Application #
3793579
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications